Browse Articles

Discover research articles across all indexed journals

Effect of gamma irradiation on optical, magnetic and structural properties of AgMnFe2O4 nanoparticles

Scientific Reports Alireza Meidanchi, Mona Ashouri, Morteza Mohseni Jul 10, 2026 DOI: 10.1038/s41598-026-61277-0

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial

Journal of Clinical Oncology Run-Cong Nie, Ying Jin, Cheng-Cai Liang et al. Jul 10, 2026 DOI: 10.1200/jco-25-02842

The NEOSUMMIT-01 trial previously showed that adding the PD-1 antibody toripalimab to perioperative chemotherapy improved the pathologic response in patients with locally advanced gastric or gastroesophageal junction cancer. Here, we present the event-free survival (EFS) and overall survival (OS) after extended follow-up. A total of 108 patients were enrolled (toripalimab plus chemotherapy, n = 54; chemotherapy alone, n = 54). At the data cutoff date (August 29, 2025), the median follow-up was 43.2 months (interquartile range: 36.6-53.7). The 3-year EFS was 74.7% (95% CI, 63.6% to 87.7%) in the toripalimab plus chemotherapy group and 56.2% (95% CI, 43.3% to 73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.51 (95% CI, 0.27 to 0.98; P = .044). The 3-year OS was 81.3% (95% CI, 71.4% to 92.4%) versus 72.2% (95% CI, 61.2% to 85.2%), respectively, with an HR of 0.45 (95% CI, 0.21 to 0.95; P = .036). The survival benefits were consistent across most predefined subgroups and were maintained in the analysis excluding patients with dMMR. In conclusion, perioperative toripalimab plus chemotherapy significantly improved 3-year EFS and OS compared with chemotherapy alone, suggesting it as a promising treatment option for patients with locally advanced gastric or gastroesophageal junction cancer.

Origin of crack propagation in lithium cobalt oxide positive electrode for lithium-ion batteries

Nature Communications Wenguang Zhao, Zijian Li, Mingyang Li et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75373-2

Could molecular variations be predictive in right and left colon cancer in different gender and age groups?

PLoS ONE Hatice Cilem Solak, Nazli Mert, Asim Leblebici et al. Jul 10, 2026 DOI: 10.1371/journal.pone.0351228

Background Left-sided colon-cancer (LCC) and right-sided colon cancer (RCC) harbor different clinical entities and different therapy protocols. Our study aimed to demonstrate genomic expression differences and clarify the clinical differences between LCC and RCC by using in-silico methods. Methods Our study compares mRNA expression levels between clinical groups to describe variations in molecular characteristics between right-left-sided colon cancer (216 right-141 left) using the TCGA-COAD database. We identified differentially expressed genes and analyzed survival profiles for RCC and LCC. We applied a gene set enrichment analysis and merged the results by group to highlight common and different pathways. Results The results reveal that TG, INSL5, EREG and AIRE were found as age-related genes, and TG, INSL5, EREG, AIRE, HOXB8 and FLT3 were found as gender-related genes for RCC and LCC. We found that high expression of the AIRE gene was linked with poor survival in patients with RCC in males and under 65 age groups. High expression of LEP was correlated with poor survival in patients with RCC, regardless of gender. In addition, low expression of the EREG gene was linked with poor survival in women with RCC. Conclusions Three genes (AIRE, LEP, EREG), which are effective on the EGFR pathway, would have great predictive and prognostic importance in the context of anti-EGFR therapies.

Domain-specific perceptual grouping of human dyads: evidence from autistic trait profiles

Scientific Reports Bethany E. Richards, James T. Enns, Kim Shapiro et al. Jul 10, 2026 DOI: 10.1038/s41598-026-61597-1

Abstract A longstanding debate in social cognition centres on distinguishing between cognitive processes that are specialised for social content and those that function across multiple domains. Recent research shows that the visual processing of human figures in apparent social interactions is marked by early perceptual grouping. However, whether perceptual grouping of social scenes occurs through a social-specific or domain-general mechanism remains unclear. We examined this question by investigating the relationship between individual differences in social aptitude and perceptual grouping in geometric and social domains. Participants ( n  = 172) completed selective and integrative attention tasks featuring visual displays of geometric and human dyads. Their accuracy and reaction times were measured, and individual social traits were assessed using Autism Quotient Questionnaire subscales. Both geometric and social stimuli showed significant perceptual grouping effects, characterised by faster processing under integrative attention and slower processing under selective attention. Notably, individuals with higher social autistic traits tended to show selective difficulties in social perceptual grouping while maintaining intact geometric grouping, a pattern consistent with domain-specific processes in social scene processing. These findings suggest that even fundamental visual processes may be specifically tuned for social perception, with potential implications for understanding individual differences in social cognition.

Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?

Journal of Clinical Oncology Laure-Anne Teuwen, Rachel P. Riechelmann, Bishal Gyawali Jul 10, 2026 DOI: 10.1200/jco-25-02619

Enhancing the strain limit of stretchable organic transistors by Schottky barrier-dominated transport mode

Nature Communications Yao Fu, Xinran Zheng, Shuguang Wang et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75302-3

Barriers and facilitators to hepatitis C patient engagement: Interview study with general practitioner champions in England

PLoS ONE Avelie Stuart, Carina Hörst, Dolores Mullen et al. Jul 10, 2026 DOI: 10.1371/journal.pone.0337867

There are people living with a previously diagnosed chronic hepatitis C infection who have been lost to follow up, and people who may have undiagnosed hepatitis C. General Practitioners (GPs) could help to support these patients into care, via offering testing, referring to secondary care, and facilitating prescribing. We conducted semi-structured interviews with 14 GPs, most of whom work with local Operational Delivery Networks (ODNs) with funding from the NHS England Viral Hepatitis Programme as hepatitis C GP Champions. A thematic analysis with a multi-level model (system, provider-levels) and the COM-B (capability, opportunity, motivation: behaviour) framework were used to identify barriers and facilitators to patient identification and (re)engagement. System-level barriers included a lack of hepatitis C incentives for GPs, pressures facing primary care, challenges searching patient records, and a perception that better processes are needed to re-engage patients lost to follow up. GP Champions expressed challenges coordinating regional patient (re)engagement strategies, but also reported successful collaborations with ODNs, other services, and outreach/community partners. Provider-level barriers for all GPs included lack of knowledge of hepatitis C and difficulty managing patient conversations (capability); and lack of GP capacity and difficulty contacting patients (opportunity). Provider-level facilitators included that primary care is holistic and accessible to patients (opportunity), and GP Champions reported how their roles have granted workload capacity and the support of other GPs/healthcare professionals (opportunity) and increased their feelings of personal reward (motivation). Interviewees’ reflections on shared care and their suggestions for the future of hepatitis C care are also presented. This study demonstrates numerous benefits to employing GP Champions to find and offer testing to patients, however system-level barriers are notably persistent. Interviewees said there is further need to address patients holistically, and joint efforts between services/sectors were suggested as means to overcome system and provider level barriers.

Forecasting USD PKR exchange rates using Urdu social media sentiment

Scientific Reports Abid Sohail, Muhammad Rizwan, Muhammad Salman Ali et al. Jul 10, 2026 DOI: 10.1038/s41598-026-61286-z

Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology

Journal of Clinical Oncology Jian Xu, Guo Wu, Jingdong Li Jul 10, 2026 DOI: 10.1200/jco-25-01989

Photosystem I-independent oxygenic photosynthesis in cyanobacteria

Nature Communications Marta Ludwiczak, Marcel Dann, Theo Figueroa-Gonzalez et al. Jul 10, 2026 DOI: 10.1038/s41467-026-74903-2

Abstract Oxygenic photosynthesis generates ATP and NADPH via linear electron flow from water to NADP + , a process thought to require photosystem I (PSI) for reductant formation. Here we demonstrate that oxygenic photosynthesis can operate without PSI in the cyanobacterium Synechocystis sp. PCC 6803. Using genetic engineering and adaptive laboratory evolution, we obtained PSI-deficient lineages capable of photoautotrophic growth, inorganic carbon fixation, and light-driven oxygen evolution. PSI-independent photoautotrophy arose from co-mutations in at least two proteins, including the translation elongation factor G (FusA), and required a functional NDH-1 complex. We propose that the light-driven electron transport in the evolved strains is reorganised in two branches: one involving terminal oxidases to generate proton motive force, and a second in which reverse NDH-1 activity exploits this gradient to produce reductant. These findings uncover unexpected plasticity in the thylakoid electron transport network and prompt a reassessment of the canonical requirement for PSI in oxygenic photosynthesis.

Heptapharmacological activity of Quercetin-3-O-phosphate against lung cancer pathways

PLoS ONE Maryam Abdulrahman Alahdal, Hadil Alahdal, Najat Binothman et al. Jul 10, 2026 DOI: 10.1371/journal.pone.0349042

Lung cancer is one of the leading causes of cancer-related deaths globally, with smoking being the primary risk factor, though environmental exposures and genetic mutations also play significant roles. Lung cancer arises when abnormal lung cells grow uncontrollably, leading to over 2 million new cases and nearly 1.8 million deaths globally. Drug resistance, especially to targeted therapies, is a key challenge, as tumours often adapt and become unresponsive. Multitargeted drug design, which targets multiple pathways involved in tumour growth, offers a promising solution to overcome resistance and improve treatment efficacy. In this study, we identified several lung cancer–associated proteins: CK2, Ran–Importin β complex, HNGF, Human Survivin, CRK-II adaptor protein, AKR1B10, and tRNA dihydrouridine synthase 2, with respective PDB IDs 1JWH, 1IBR, 1SG1, 1XOX, 2DVJ, 4XZL, and 4XP7. We conducted molecular docking using DrugBank’s library, employing HTVS, SP, and XP, followed by pose processing with MM/GBSA. Our multitarget docking analysis identified Quercetin-3-O-Phosphate as the top compound, a quercetin derivative found in fruits and vegetables such as onions, apples, berries, broccoli, and citrus. The compound showed docking and MM/GBSA scores ranging from −5.835 to −11.627 Kcal/mol and −14.28 to −47.07 Kcal/mol, respectively, and the key interacting residues with their counts include 10ASP, 9LEU, 9LYS, 7ALA, 7ARG, 7TYR, 6GLN, 5ASN, 5GLU, 5ILE, and 5VAL. We also performed and analysed DFT and pharmacokinetics in detail, which supported its further evaluation as it met all the required criteria. We conducted a 5 ns WaterMap simulation, which confirmed the interactions and highlighted key hydration sites that support the complex’s stability. A 100 ns MD simulation using the TIP3P water model showed minimal deviation and fluctuations, indicating stable interactions and the trajectories used for MM/GBSA calculations, assessing binding free, which reinforced the stability of the complexes and helped rank the best candidates. All results indicate that Quercetin-3-O-Phosphate holds strong potential for lung cancer treatment, though experimental validation is needed for clinical confirmation.

Sociodemographic and health determinants of handgrip strength in adults living in rural Ecuador

Scientific Reports Alejandra Hurtado-Encalada, Jorge Palacios-Piedra, Tamara Rodríguez Quintana et al. Jul 10, 2026 DOI: 10.1038/s41598-026-57606-y

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors

Journal of Clinical Oncology Manish R. Sharma, John Powderly, Yasutoshi Kuboki et al. Jul 10, 2026 DOI: 10.1200/jco-25-01525

PURPOSE The antibody-drug conjugate Temab-A comprises the c-Met–targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882 ) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion. METHODS Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg/kg in dose escalation. In mCRC dose expansion, patients with confirmed BRAF wild-type, microsatellite stable/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg/kg, 2.4 mg/kg, or 3.0 mg/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC. RESULTS In total, 57 patients received ≥1 dose of Temab-A in dose escalation; 3.0 mg/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced ≥1 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg/kg and 3.0 mg/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1). CONCLUSION Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.

Resting-state electroretinography reveals pathological retinal oscillations in retinitis pigmentosa mice and patients

Nature Communications David G. Litvin, Alexia Boizot, Andrea Corna et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75520-9

Abstract Retinal remodeling occurs in both retinitis pigmentosa and age-related macular degeneration. However, it is still unknown whether spared retinal circuits are also functionally altered. Functional changes have been observed in animal models of retinitis pigmentosa, including the emergence of bursting oscillatory activity in retinal ganglion cells. Yet, comparable oscillatory activity, or other functional alterations, has not been demonstrated in patients. To address this gap, here we report a non-invasive corneal neurotechnology measuring in-vivo resting-state electroretinography and analyzing its frequency content and temporal characteristics to identify biomarkers of functional remodeling. We document that retinal remodeling induces bursting oscillatory activity in-vivo in retinitis pigmentosa mouse models and translate these results to patients. Moreover, we showed in mice that bursting oscillatory activity can be pharmacologically modulated in-vivo. Furthermore, reducing this oscillatory activity increases retinal excitability to electrical stimulation. These results are crucial for a better understanding of retinal degeneration and contribute to sight restoration efforts.

Modal analysis of the vibrational characteristics of a 12U nanosatellite in various deployers

Scientific Reports Muslim Mukhtarkhanov, Dulat Akzhigitov, Berik Zhumazhanov et al. Jul 10, 2026 DOI: 10.1038/s41598-026-61296-x

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Journal of Clinical Oncology Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen et al. Jul 10, 2026 DOI: 10.1200/jco-25-03120

PURPOSE Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous, aggressive lymphomas. Five-year overall survival (OS) remains approximately 30%-40%, and most patients will develop relapsed or refractory (R/R) disease. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms. Here, we report on the final analysis of the phase II PRIMO trial (ClinicalTrials.gov identifier: NCT03372057 ; Secura Bio, Inc) evaluating duvelisib monotherapy in R/R PTCL. METHODS PRIMO was conducted in two phases (dose optimization and dose expansion [PRIMO-EP]) at 45 centers globally. Eligible patients were age 18 years and older, had histologically confirmed diagnosis of PTCL, and had received ≥2 cycles of one standard regimen for PTCL. Based on dose optimization results, the selected regimen for PRIMO-EP was 75 mg twice a day for two cycles (to maximize disease control) followed by 25 mg twice a day (to reduce late toxicities), continued until progressive disease or unacceptable toxicity. RESULTS PRIMO-EP (N = 123) outcomes included independent review committee–assessed objective response rate (ORR): 48.0%, complete response rate (CRR): 33.3%, median progression-free survival (mPFS): 3.4 months, median OS (mOS): 12.4 months, and median duration of response (mDOR): 7.9 months. In the angioimmunoblastic T-cell lymphoma (AITL) subgroup, outcomes were ORR: 62.2%, CRR: 51.4%, mPFS: 8.3 months, mOS: 18.1 months, and mDOR: 11.3 months. Treatment-emergent adverse events (TEAEs; any grade) occurred in 120 patients (97.6%), and TEAEs grade ≥3 occurred in 91 patients (74.0%). TEAEs resulting in dose hold or dose reduction occurred in 44.7% and 9.8% of patients, respectively. CONCLUSION The PRIMO study demonstrates significant activity and tolerability of duvelisib in patients with R/R PTCL, most notably in the AITL subgroup. This provides strong rationale for further development in PTCL, and more specifically in the subgroup of nodal T-follicular helper cell lymphoma.

Modulating the interfacial solvation structure to promote hydroxyl migration for alkaline hydrogen oxidation

Nature Communications Chenggong Niu, Yulin Zhao, Yuchen Lei et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75394-x

Trade induced extinction risk footprints by European financial institutions

Scientific Reports Siwar Ortiz-Guzman, Julien Calas, Antoine Godin et al. Jul 10, 2026 DOI: 10.1038/s41598-026-58778-3

Abstract Biodiversity loss is increasingly recognized as a source of systemic financial risk. The financial sector enables economic activities that exert pressure on ecosystems, sometimes far from where capital is held, so institutions in one region can enable biodiversity loss elsewhere by financing seemingly harmless sectors with value-chain links to harmful activities. We establish a novel correspondence matrix linking 104 environmental pressures to 124 IUCN biodiversity threats, and combine it with the GLORIA input–output model to quantify species extinction-risk for 164 countries. Particulate matter, land-use change, and nitrogenous gases are the most damaging pressures, exerted mainly by agriculture, manufacturing, and construction. Seventy-four countries are net importers of extinction risk and twenty-three net exporters; all twelve European countries analysed are importers, with approximately 40% of their financial assets linked to extinction-risk sectors. Because these pressures are so embedded in production, a 1% reduction in the extinction-risk footprint propagates almost one-for-one through the economy: output falls by about 0.88% on average, while firms’ capacity to service debt weakens as revenues drop but interest obligations hold fixed. This exposes how structurally dependent financial systems are on nature-harming activity, supporting efforts to disclose and reduce holdings of assets linked to biodiversity loss.

Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”

Journal of Clinical Oncology Arnaud Scherpereel, Aaron S. Mansfield, Francesco Grossi et al. Jul 10, 2026 DOI: 10.1200/jco-26-01153